Time filter

Source Type

Busquet F.,European Commission - Joint Research Center Ispra | Busquet F.,Center for Alternatives to Animal Testing Europe | Strecker R.,University of Heidelberg | Strecker R.,SCC GmbH | And 28 more authors.
Regulatory Toxicology and Pharmacology | Year: 2014

A The OECD validation study of the zebrafish embryo acute toxicity test (ZFET) for acute aquatic toxicity testing evaluated the ZFET reproducibility by testing 20 chemicals at 5 different concentrations in 3 independent runs in at least 3 laboratories. Stock solutions and test concentrations were analytically confirmed for 11 chemicals. Newly fertilised zebrafish eggs (20/concentration and control) were exposed for 96. h to chemicals. Four apical endpoints were recorded daily as indicators of acute lethality: coagulation of the embryo, lack of somite formation, non-detachment of the tail bud from the yolk sac and lack of heartbeat. Results (LC50 values for 48/96. h exposure) show that the ZFET is a robust method with a good intra- and inter-laboratory reproducibility (CV. <. 30%) for most chemicals and laboratories. The reproducibility was lower (CV > 30%) for some very toxic or volatile chemicals, and chemicals tested close to their limit of solubility. The ZFET is now available as OECD Test Guideline 236.Considering the high predictive capacity of the ZFET demonstrated by Belanger et al. (2013) in their retrospective analysis of acute fish toxicity and fish embryo acute toxicity data, the ZFET is ready to be considered for acute fish toxicity for regulatory purposes. © 2014 The Authors.

PubMed | University of Tübingen, University Hospitals Leuven, University of Tampere, The Innovation Group and 14 more.
Type: | Journal: Drug discovery today | Year: 2016

Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.

Loading Center for Alternatives to Animal Testing Europe collaborators
Loading Center for Alternatives to Animal Testing Europe collaborators